Alpa Laboratories Ltd Falls to 52-Week Low of Rs.63.76 Amid Continued Downtrend

Stock Price Movement and Market Context

On 21 Jan 2026, Alpa Laboratories Ltd’s share price fell to an intraday low of Rs.63.76, representing a 3.39% drop on the day. This decline extends a three-day losing streak during which the stock has shed 11.51% in value. The stock’s current price is substantially below its 52-week high of Rs.136.90, reflecting a near 53.4% depreciation over the past year.

The stock’s underperformance is further highlighted by its relative weakness against the Pharmaceuticals & Biotechnology sector, where it lagged by 2.89% on the same day. Additionally, Alpa Laboratories is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling sustained downward momentum.

Meanwhile, the broader market has also been under pressure. The Sensex opened 385.82 points lower and closed down 266.74 points at 81,527.91, a 0.79% decline. The index has been on a three-week losing streak, falling 4.94% in that period. Although the Sensex trades below its 50-day moving average, the 50DMA remains above the 200DMA, indicating some underlying resilience in the broader market.

Financial Performance and Profitability Concerns

Alpa Laboratories’ financial metrics reveal challenges that have contributed to the stock’s decline. The company reported a negative Profit Before Tax (PBT) excluding other income of Rs. -2.95 crores in the September 2025 quarter, a steep fall of 619.8% compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) for the quarter was Rs.0.11 crores, down 98.3% from the prior four-quarter average.

Return on Capital Employed (ROCE) for the half-year stood at a low 12.57%, indicating subdued efficiency in generating returns from capital invested. The company’s operating profit has contracted sharply over the last five years, with an annualised decline rate of 206.03%, underscoring persistent difficulties in sustaining growth.

Moreover, the stock’s earnings before interest, taxes, depreciation and amortisation (EBITDA) have been negative, adding to concerns about profitability. Over the past year, profits have fallen by 10.4%, compounding the pressure on the stock price.

Long-Term Performance and Valuation

Alpa Laboratories has delivered a one-year total return of -50.05%, significantly underperforming the Sensex, which gained 7.50% over the same period. The stock has also lagged the BSE500 index across multiple time frames, including the last three years, one year, and three months, reflecting below-par performance relative to broader market benchmarks.

The company’s Mojo Score stands at 17.0, with a Mojo Grade of Strong Sell as of 17 Nov 2025, an upgrade from the previous Sell rating. This grading reflects the deteriorated financial health and risk profile of the stock. The Market Cap Grade is rated 4, indicating a relatively modest market capitalisation within its sector.

Despite the challenges, the company maintains a low average Debt to Equity ratio of zero, suggesting limited leverage and a conservative capital structure. Promoters remain the majority shareholders, maintaining control over the company’s strategic direction.

Summary of Key Metrics

To summarise, Alpa Laboratories Ltd’s recent stock price decline to Rs.63.76 marks a new 52-week low amid a challenging financial backdrop. The company’s negative quarterly PBT and PAT figures, low ROCE, and negative EBITDA highlight ongoing difficulties in profitability and growth. The stock’s underperformance relative to the Sensex and sector peers further emphasises the pressures faced by the company.

While the company’s low debt levels and promoter majority ownership provide some stability, the overall financial and market indicators suggest a cautious outlook on the stock’s near-term trajectory.

Unlock special upgrade rates for a limited period. Start Saving Now →